Cardiologists involved in obesity research have raised particular concern about sympathomimetic-GLP-1 combinations in patients with hypertension, arrhythmia history, or coronary artery disease
This suggests that semaglutide may cause early worsening of DR, especially in patients with poor glycemic control, highlighting the importance of monitoring DR during GLP-1 RA therapy
With annual costs exceeding $15,000 for medications like Wegovy, many patients find themselves paying premium prices while waiting months to see significant changes
A minimum of three months may be required before observing an effect
Here are some crucial lifestyle considerations for individuals thinking about semaglutide: Balanced Diet and Nutrition : Pairing semaglutide with a balanced, calorie-conscious diet enhances its appetite-suppressing effects
Always seek the advice of your healthcare provider first